NMPA Accepts sNDA for Toripalimab Plus Bevacizumab as Frontline Therapy in Advanced HCC
The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.
Related Articles
Fundamental Research Paved the Way for the Development of Vorasidenib
Vorasidenib is a new promising clinical treatment for gliomas. However, this recent breakthrough in the treatment of brain tumors is only a snapshot of a…
Cancer rarely travels alone: Addressing the accumulation of risk and early mortality for older adults with advanced lung cancer
Lung cancer kills more people globally than any other cancer [1]. In the United States, it is responsible for more cancer-related deaths than breast, prostate,…
Science Talk – “Our underlying motivation has an emotional core” – en
Childhood cancer treatment is challenging, with certain cancer types proving particularly difficult to treat. Although researchers have made significant progress, the outlook for children with…
Stakeholder Connect | Supreme Court Decisions and Their Impact on the FDA and Patients’ Lives: The Overruling of Chevron – Friends of Cancer Research
What is Chevron deference, how did it come to be, and what were the implications for FDA? Chevron deference was established by the 1984 Supreme…
Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC
Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.
Abnormal Uterine Bleeding and the Risk of Endometrial Cancer
Researchers developed a predictive model to assess endometrial hyperplasia and cancer risk in patients with recurrent abnormal uterine bleeding. Learn more.
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In the phase III HARMONi-2 study conducted in China, presented at the IASLC 2024 World Conference on Lung Cancer, the bispecific antibody ivonescimab was compared…
Speed Mentoring – 2024 Annual Meeting – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
#ASTRO24 Speed Mentoring extends a warm invitation to all Annual Meeting registrants eager to connect with ASTRO leaders and gain valuable insights for both career…
Mirvetuximab Soravtansine Shows Efficacy in Ovarian Cancer Despite Dose Adjustments
In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.
Prevention and management of indwelling catheter‐related thrombosis in sickle cell disease and thalassaemia: A British Society for Haematology Good Practice Paper
Click on the article title to read more.
